Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RBC Capital Markets initiated coverage on Alpine Immune Sciences Inc (NASDAQ: ALPN), noting that the autoimmune disease market (over $165 billion) is meaningful for the company's lead candidate - povetacicept
SEATTLE--(BUSINESS WIRE)--Oct 4, 2023--
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) and Revolution Medicines (NASDAQ:RVMD – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership. Insider and Institutional Ownership 14.6% of Adaptimmune Therapeutics […]
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) and Vaxcyte (NASDAQ:PCVX – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership. Volatility & Risk Adaptimmune Therapeutics has a beta of […]
Vaxcyte (NASDAQ:PCVX – Get Free Report) and Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations. Analyst Recommendations This is a breakdown of current ratings […]